• Takashi Hirai, Mitsuhiro Enomoto, Hidetoshi Kaburagi, Shinichi Sotome, Kie Yoshida-Tanaka, Madoka Ukegawa, Hiroya Kuwahara, Mariko Yamamoto, Mio Tajiri, Haruka Miyata, Yukihiko Hirai, Makoto Tominaga, Kenichi Shinomiya, Hidehiro Mizusawa, Atsushi Okawa, and Takanori Yokota.
• Department of Orthopaedic Surgery, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
• Mol. Ther. 2014 Feb 1;22(2):409-19.

AbstractGene therapy for neuropathic pain requires efficient gene delivery to both central and peripheral nervous systems. We previously showed that an adenoassociated virus serotype 9 (AAV9) vector expressing short-hairpin RNA (shRNA) could suppress target molecule expression in the dorsal root ganglia (DRG) and spinal cord upon intrathecal injection. To evaluate the therapeutic potential of this approach, we constructed an AAV9 vector encoding shRNA against vanilloid receptor 1 (TRPV1), which is an important target gene for acute pain, but its role in chronic neuropathic pain remains unclear. We intrathecally injected it into the subarachnoid space at the upper lumbar spine of mice 3 weeks after spared nerve injury (SNI). Delivered shTRPV1 effectively suppressed mRNA and protein expression of TRPV1 in the DRG and spinal cord, and it attenuated nerve injury-induced thermal allodynia 10-28 days after treatment. Our study provides important evidence for the contribution of TRPV1 to thermal hypersensitivity in neuropathic pain and thus establishes intrathecal AAV9-mediated gene delivery as an investigative and potentially therapeutic platform for the nervous system.

44 keywords...

hide…